Skip to main content

Table 1 Demographic information for enrolled clinically suspected early stage AD subjects

From: Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease

Amyloid PETPositiveNegativeAll
Numbers (% female)22 (50.0%)30 (36.7%)52 (42.3%)
Age (years)72.1 ± 7.671.9 ± 9.772.0 ± 8.8
Education (years)12.0 ± 4.311.0 ± 3.611.4 ± 3.9
Clinical stage
 aMCI82533
 Mild dementia14519
APOE ε4 carrier12214
CDR0.50.50.5
MMSE24.0 ± 2.727.0 ± 2.225.8 ± 2.8
Logical memory delayed recall5.41 ± 3.928.40 ± 5.12*7.13 ± 4.84
  1. Abbreviations: AD Alzheimer’s disease, CDR Clinical Dementia Rating Scale, MMSE Mini-Mental State Examination, PET positron emission tomography
  2. *P value < 0.05
  3. P value < 0.001